MHC II-restricted peptide vaccines can elicit NeoAg-specific Th1 immunity that orchestrates tumor-reactive CD8+ cytotoxic T lymphocyte (CTL) responses, for example, by increasing the number of antigens available to cytotoxic CD8+ T cells through the restoration of MHC class I expression on tumor and immune cells, providing cytokines to facilitate CD8+ responses, and by facilitating the generation of robust immunologic memory. Here, CD8A is linked to neoplasm.